Company Information
USD
235.32
- (3.7%)
NASDAQ:BIIB, BIOGEN INC.
Industry: Drug Manufacturers - General
End of Day: 15 May 2024 GMT-4
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.
Address
225 Binney Street
Website
Classification
Sector
Healthcare
Industry Group
Drug Manufacturers
Industry
Drug Manufacturers - General
Key Executives
Ms. Caroline D. Dorsa
Chairman of the Board/Director
Dr. Eric K. Rowinsky,M.D.
Director
Mr. William A. Hawkins, III
Director
Mr. Michael R. Mcdonnell
CFO/Executive VP
Dr. Stephen A. Sherwin, M.D.
Director
Mr. Christopher A. Viehbacher
CEO/Director/President
Ms. Susan H. Alexander
Chief Legal Officer/Executive VP
Dr. Ginger Gregory, PhD
Executive VP/Other Executive Officer
Dr. Maria C. Freire, PhD
Director
Ms. Robin C. Kramer
Chief Accounting Officer/Senior VP
Dr. Priya Singhal, M.D.,M.P.H.
Executive VP/Other Corporate Officer
Mr. Jesus B. Mantas
Director
Mr. Monish D. Patolawala
Director
Dr. Jane Grogan, PhD
Executive VP, Divisional
Mr. Rachid Izzar
Executive VP, Divisional
Ms. Nicole Murphy
Executive VP, Divisional
Mr. Adam Keeney, PhD
Executive VP, Divisional
Ms. Susan Langer
Director
Ownership
Institution Holdings
PRIMECAP Management Company
16,264,481 (11.189%)
Vanguard Group Inc
14,407,330 (9.911%)
BlackRock Inc
14,246,658 (9.801%)
State Street Corporation
6,945,665 (4.778%)
T. Rowe Price Investment Management,Inc.
5,357,326 (3.686%)
Wellington Management Company LLP
5,324,396 (3.663%)
BlackRock Fund Advisors
5,015,942 (3.451%)
JPMorgan Chase & Co
5,011,319 (3.448%)
Vanguard Investments Australia Ltd
4,641,092 (3.193%)
Invesco Capital Management LLC
3,365,875 (2.316%)
Individual Holdings
Ms. Susan H. Alexander
51,683 (0.036%)
Ms. Caroline D. Dorsa
24,822 (0.017%)
Dr. Eric K. Rowinsky,M.D.
20,629 (0.014%)
Mr. Michael R. Mcdonnell
19,406 (0.013%)
Dr. Stephen A. Sherwin, M.D.
18,738 (0.013%)
Dr. Ginger Gregory, PhD
13,584 (0.009%)
Mr. Rachid Izzar
9,701 (0.007%)
Ms. Nicole Murphy
9,418 (0.007%)
Mr. Christopher A. Viehbacher
7,000 (0.005%)
Ms. Robin C. Kramer
6,227 (0.004%)
Funds Holdings
Vanguard PrimeCap Fund
9,194,061 (6.325%)
Vanguard US Total Market Shares ETF
4,564,918 (3.140%)
Vanguard Total Stock Market Index Fund
4,564,918 (3.140%)
Vanguard Institutional 500 Index Trust
3,580,484 (2.463%)
Invesco QQQ Trust
2,731,142 (1.879%)
Vanguard Capital Opportunity Fund
2,241,937 (1.542%)
Fidelity 500 Index Fund
1,720,340 (1.184%)
SPDR® S&P 500 ETF Trust
1,700,139 (1.170%)
Vanguard Mid-Cap Index Fund
1,623,252 (1.117%)
iShares Core S&P 500 ETF
1,507,458 (1.037%)
Make Smart Investment Choices
GoodWhale Pte. Ltd.
1557 Keppel Road, #01-01
Singapore 089066
Singapore 089066
